



ABN 53 075 582 740

ASX ANNOUNCEMENT
11 May 2020

Bionomics Extends Cash Runway Through Deferral of Loan Repayments

Bionomics Limited (ASX: BNO, OTCQB:BNOEF), a global, clinical stage biopharmaceutical company, today announced that, in relation to its remaining USD 6,818,182 loan facility with Silicon Valley Bank and Oxford Finance LLC, the financiers have agreed to amend the loan facility documentation to provide for a deferral of principal repayments for a 6 month period until November 2020 and an extension of the final maturity date of the facility by 6 months to 1 January 2022. In return, Bionomics has granted further security to the financiers over its intellectual property portfolio, which was not previously the subject of security to the financiers.

Dr Errol De Souza, Executive Chairman of Bionomics said "We are pleased to have reached this accommodation with our lenders at a time when COVID-19 makes sourcing capital markets difficult and puts undue downward pressure on our share price. This extension will allow us to continue development of BNC210 for the treatment of PTSD while securing our funding requirements in an orderly manner. We look forward to providing updates on both fronts in the near future"

AUTHORISED BY: DR ERROL DE SOUZA, EXECUTIVE CHAIRMAN

FOR FURTHER INFORMATION PLEASE CONTACT:

Mr Jack Moschakis
Legal Counsel & Company Secretary
Bionomics Limited
31 Dalglish St,
Thebarton, South Australia
+61 8 8354 6100
jmoschakis@bionomics.com.au

About Bionomics Limited

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics' lead drug candidate BNC210 is a novel, proprietary negative allosteric modulator of the alpha-7 ($\alpha 7$) nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with MSD and a pipeline of pre-clinical ion channel programs targeting pain, depression, cognition and epilepsy.

www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this announcement that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug

candidates (including BNC210), its licensing agreements with MSD and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.